Lorcaserin: A novel antiobesity drug

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 2, 2014, Pages 175-178

  Brashier, Dick B S ^a   Sharma, A K ^a   Dahiya, Navdeep ^a   Singh, S K ^a   Khadka, Anjan ^a  

^a ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Lorcaserin; obesity; serotonin

Indexed keywords

DEXTROMETHORPHAN; HEMOGLOBIN A1C; KETAMINE; LORCASERIN; METFORMIN; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; TRIPLE REUPTAKE INHIBITOR; ZOLPIDEM;

ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; BEHAVIOR DISORDER; BODY MASS; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COATING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW CALORY DIET; MEMORY DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIAPISM; RASH; SATIETY; SEROTONIN BLOOD LEVEL; SEROTONIN SYNDROME; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION;

EID: 84911981354     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.130158     Document Type: Article

References (17)

1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J 2008;32:1431-75
2. Redman LM, Ravussin E. Lorcaserin for the treatment of obesity. Drugs Today 2010; 46:901-10
3. Girard C, Butler AA. Neural melanocortin receptors in obesity and related metabolic disorders. Biochim Biophys Acta 2013
4. Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, et al. Lorcaserin, a 5-HT (2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 2011; 96:837-45
5. Morgan M, Chen W, Anderson C, Prosser W, Donahue D, Shanahan W. Pharmacokinetic properties, metabolism and tolerability of lorcaserin in healthy volunteers: Phoenix: Paper presented at Annual Meeting of The Obesity Society; 2008
6. Usmani KA, Chen WG, Sadeque AJ. Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos 2012; 40:761-71
7. Sadeque AJ, Usmani KA, Palamar S, Cerny MA, Chen WG. Obes Drug Metab Dispos 2012;40:772-8
8. Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther 2011; 89:683-92
9. Hurren KM, Berlie HD. Lorcaserin: An investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm 2011; 68:2029-37
10. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al., Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. N Engl J Med 2010; 363:245-56
11. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity 2012;20:1426-36
12. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al., BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-77
13. Halford JC. Lorcaserin-not a new weapon in the battle with appetite. Nat Rev Endocrinol 2010;6:663-4
14. Bai B, Wang Y. The use of lorcaserin in the management of obesity: A critical appraisal. Drug Des Devel Ther 2010; 5:1-7
15. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. Pharmacol Exp Ther 2008; 325:577-87
16. Carter R, Mouralidarane A, Ray S, Soeda J, Oben J. Recent advancements in drug treatment of obesity. Clin Med 2012; 12:456-60
17. Taylor JR, Dietrich E, Powell JG. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. Clin Ther 2013; 35:A3-17.